ROIV 241220 10.00P (ROIV241220P10000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ROIV241220P10000

Watchlist

0.27
0.000.00%

15min DelayTrading Oct 25 11:40 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Optimistic Outlook on Roivant Sciences Despite Namilumab Setback
TipRanksDec 6 00:58 ET
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Seeking AlphaDec 3 11:49 ET
Roivant Sciences Ends Namilumab Study Due to Inefficacy
TipRanksDec 3 07:47 ET
Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study
WSJDec 3 07:35 ET
Express News | Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study
ReutersDec 3 07:05 ET
Express News | Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit
ReutersDec 3 07:00 ET

Comments

Meltyy

Dec 5 06:32

🚀 12 upcoming PDUFAs in December ❄️

Buckle up! See FDA PDUFA update 👇🧵
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...

Jaguar8

Dec 3 06:07

NEWS

$Roivant Sciences (ROIV.US)$
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
6 minutes ago, 4:00 AM PST
Via GlobeNewswire
ROIVROIVW
Share
• Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis
• Further development of namilumab for the treatment of sarcoidosis will be discontinued

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Movers and Shakers

Apr 2 07:16

Columns Today's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More

Morning Movers
Gapping up
$DoorDash (DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences (ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc (NIO.US)$ fell ...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...